Table 5.
Selected publications reporting outcome measures after multimodal treatment of craniofacial malignancies.
| Publication | Histology | Treatment | 5-year overall survival% | 5-year progression free survival% |
|---|---|---|---|---|
| Waldron et al. (15) | SCC, AC, SNUC | XRT + S | 39 | 41 |
| Paulino et al. (17) | SCC, AdCC, AC, MEC | XRT only | 0 | 18 |
| S + XRT | 52 | 50 | ||
| Le et al. (20) | SCC, AC, AdCC, SNUC | XRT only | 19 | 20 |
| S + XRT | 46 | 56 | ||
| Jansen et al. (19) | SCC, AC, AdCC, SNUC | XRT + S | 60 | 65 |
| XRT only | 9 | 47 | ||
| Tran et al. (21) | AC, AdCC, MEC | XRT + S | n/a | 18 |
| S only | n/a | 62 | ||
| S + XRT | n/a | 9 | ||
| Tiwari et al. (22) | SCC, AC, AdCC, MEC, SNUC | S + XRT | 64 | n/a |
| XRT + ChT | 37 (2-yrs) | n/a | ||
| Fernström et al. (26) | SCC, AC, AdCC, SNUC, NEC, MEC | ChT + XRT + S | 54 | 32 |
| Dulguerov et al. (18) | SCC, AC, AdCC, MEC, SNUC | S only | 79 | n/a |
| S + XRT | 66 | n/a | ||
| XRT only | 57 | n/a | ||
| Amit et al. (36) | SNUC | IC + ChT + XRT | 66 | 74 (with response to IC) |
| IC + S + XRT | 43 | 55 (with response to IC) | ||
| Yin et al. (51) | ONB | XRT+ S | 91 | 91 |
| S + XRT | 79 | 82 | ||
| XRT only | 50 | 63 | ||
| Chao et al. (55) | ONB | S + XRT | 67 | 87 |
| XRT only | n/a | 51 | ||
| S only | n/a | 0 | ||
| Dulguerov et al. (61) | ONB | S + XRT | 65 | n/a |
| XRT + ChT | 51 | n/a | ||
| S only | 48 | n/a | ||
| S + XRT + ChT | 47 | n/a | ||
| XRT only | 37 | n/a | ||
| De Bonnecaze et al. (50) | ONB | S + XRT | 73 | n/a |
| S + XRT + ChT | 64 | n/a | ||
| S only | 58 | n/a | ||
| ChT + XRT | 32 | n/a | ||
| XRT only | 29 | n/a | ||
| ChT only | 53 | n/a | ||
| Amit et al. (67) | MA | S + ChT + XRT | 47 | n/a |
| S + XRT | 42 | n/a | ||
| S only | 39 | n/a | ||
| ChT + S + XRT | 27 | n/a | ||
| Samstein et al. (71) | MA | S + XRT | n/a | 59 |
| S only | n/a | 35 | ||
| Benlyazid et al. (136) | MA | S + XRT | 28 | 29 |
| S only | 46 | 27 | ||
| Kaur et al. (180) | M WHO II | S + XRT | 68 | 54 |
| M WHO III | S + XRT | 56 | 48 | |
| Aghi et al. (173) | M WHO II | S + XRT | n/a | 100 |
| S only | n/a | 44 | ||
| Mair et al. (181) | M WHO II | S + XRT | n/a | 60 |
| S only | n/a | 50 | ||
| Dziuk et al. (167) | M WHO III | S + XRT | n/a | 80 |
| S only | n/a | 15 | ||
| Jasnau et al. (88) | OS | ChT + S | 75 | 52 |
| Cht + S + XRT | 80 (2-yrs) | n/a 60 | ||
| S only | 67 | |||
| Mucke et al. (90) | OS | ChT + S | 67 | n/a |
| S only | 42 | n/a | ||
| Kassir et al. (94) | OS | S only | 46 | n/a |
| S + XRT | 20 | n/a | ||
| S + ChT | 50 | n/a | ||
| S + XRT + ChT | 67 (2-yrs) | n/a |
S, surgery; XRT, radiotherapy; ChT, chemotherapy; IC, induction chemotherapy; SCC, squamous cell carcinoma; AC, adenocarcinoma; AdCC, adenoid cystic carcinoma; MED, mucoepidermoid carcinoma; SNUC, sinonasal undifferentiated carcinoma; NEC, neuroendocrine carcinoma; ONB, olfactory neuroblastoma; MA, melanoma; M, meningioma; OS, osteosarcoma; n/a, not available.